| Publications | PubMed=1067619; DOI=10.1073/pnas.73.9.3278; PMCID=PMC431008
Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F., Old L.J.
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976) PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977) PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812
Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F., Old L.J.
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980) DOI=10.1007/978-1-4615-7228-2_39
Houghton A.N., Oettgen H.F., Old L.J.
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981) PubMed=6197381; DOI=10.1002/ijc.2910320610
Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.
A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum.
Int. J. Cancer 32:717-721(1983) PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) Patent=US4591572
Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.
Pigmentation associated, differentiation antigen of human melanoma and autologous antibody.
Patent number US4591572, 27-May-1986 PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=7747814; PMCID=PMC1869278
Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H., Cordon-Cardo C., Kamb A.
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014
Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H.F., Liu C., Merghoub T., Hefter B.E., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R.D., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) |
|---|
